Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02951195 | A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis | PHASE2 | COMPLETED | 80 | — | — | Nov 1, 2016 | Jan 1, 2018 | Jan 28, 2021 | 16 | United States |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Arm | Type | Description |
|---|---|---|
| Part 1: Placebo | PLACEBO_COMPARATOR | - |
| Part 1 Cohort 1A: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1B: TC | EXPERIMENTAL | - |
| Part 1 Cohort 1C: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2A: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2A: TC | EXPERIMENTAL | - |
| Part 2 Cohort 2B: TEZ/IVA | ACTIVE_COMPARATOR | - |
| Part 2 Cohort 2B: TC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VX-152 | DRUG | Tablet for oral administration. |
| TEZ/IVA | DRUG | Fixed-dose combination tablet for oral administration. |
| IVA | DRUG | Tablet for oral administration. |
| Placebo | DRUG | Placebo matched to VX-152. |
Inclusion Criteria: * Willing and able to comply with scheduled visits, treatment pan, study restrictions, laboratory tests, contraceptive guidelines, and other study procedures. * Body weight ≥35 kg. * Sweat chloride value ≥ 60 mmol/L from test results obtained during screening. * Subjects must ha...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 9 | PHASE3 | VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, VNZ/TEZ/D-IVA, VX-522 mRNA therapy |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719, SION-451, SION-2222, SION-109 |
| BiomX Ltd | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | — | Undisclosed |